After undergoing years of stock market decline as reporting and awareness about the COVID-19 pandemic subsided, major vaccine stocks received a major, if grim, boost in early 2025.Specifically, researchers have been tracking with growing concern the ill-documented spread of new H5N1 (Avian Influenza or Bird Flu) variants, with some even warning that the U.S. has completely lost track of the illness by late 2024.Indeed, multiple health experts have spoken about insufficient tracking of contagion, with many c ...

Moderna (MRNA) shares soared 11.7% in the last trading session to close at $47.53. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.8% loss over the past four weeks.The surge in stock price came as investors turned their attention toward the potential demand for vaccines targeting the H5N1 virus, also known as bird flu. On Monday, the U.S. CDC reported the first human death in the country from bird flu. The company is currently ...

Stock Performance and Market Reaction - Moderna shares surged 12% to $47 53 on Tuesday driven by investor optimism around the company's development of an H5N1 bird flu vaccine following the first reported death linked to the disease in the US [2][10] - The stock has shown a strong start to the year after losing more than half of its value in 2024 due to declining demand for its Covid-19 products [3] - The stock closed decisively above the 50-day moving average on the highest trading volume since December's triple witching session indicating bullish momentum [4][10] Technical Analysis and Key Price Levels - The relative strength index (RSI) confirms bullish momentum with a reading above 65 but remains below overbought levels suggesting room for further price appreciation [4] - Key overhead resistance levels to watch include $57 near the upper level of a consolidation period from October to November 2023 $72 near the early-September low and subsequent countertrend peak and $85 near a multi-month horizontal line connecting the February low with August price points [6][7] - Important support levels to monitor include $44 where the 50-day MA and a short-term trendline converge and $37 near the November swing low which could present buying opportunities during pullbacks [8] Strategic Considerations for Investors - Investors who purchased the stock at lower levels may consider offloading shares around the $85 level due to potential resistance from the falling 200-day MA [7] - A close above the $57 resistance level could signal further upward momentum potentially driving the stock toward the $72 and $85 levels [6][7] - A breakdown below the $44 support level could lead to a retest of the $37 level offering potential entry points for new investors [8]

Without our health… time to look at Moderna’s stock (NASDAQ: MRNA).In my Outlook 2025, I list 10 stock picks. I also end the picks section with Honorable Mention stocks that I describe as “These stocks faced challenges in 2024, but as we approach 2025, they show promising fundamentals and charts with clear support levels and obvious breakout points.”Moderna (MRNA) is first on that list. Sign up for our FREE newsletter and receive our best trading ideas and research Leave this field empty if you're ...

Key TakeawaysThe S&P 500 fell 1.1% on Tuesday, Jan. 7, as U.S. manufacturing data reinvigorated concerns about inflation and the interest rate outlook.Shares of data analytics software firm Palantir lost ground for the second straight session after Morgan Stanley analysts cited valuation concerns.Moderna shares surged as reports of the country's first bird-flu fatality sparked interest in the biotech firm's experimental H5N1 vaccine. Major U.S. equities indexes lost ground as the latest Purchasing Managers' ...

Key TakeawaysModerna shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S.The biotech company is developing a vaccine for H5N1.Despite Tuesday's gains, Moderna shares are down more than 55% over the past year. Moderna (MRNA) shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1. On Monday, the Centers for Disease Contro ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day. This change lagged the S&P 500's 1.26% gain on the day. Elsewhere, the Dow saw an upswing of 0.8%, while the tech-heavy Nasdaq appreciated by 1.77%.The the stock of biotechnology company has fallen by 2.19% in the past month, leading the Medical sector's loss of 6.56% and the S&P 500's loss of 2.82%.Market participants will be closely following the financial results of Moderna in its upcoming release ...

Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatments, including those using CGT, as well as, their capacity to drive shareholders' returns. Thus, as SA analyst, I will be focusing on analysing biotechnology, pharmac ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna (MRNA) have been sliding down over the past few years due to waning demand for the vaccine.In the past three months, MRNA stock has lost nearly 40%, significantly underperforming the industry’s 17.1% decline, as seen in the chart below. While the company’s pipeline progress has been encouraging, the update to its business outlook for the next four years and a curtailed R&D budget did not sit well ...